Bulletin de l'Institut Pasteur
Volume 95, Issue 4, October–December 1997, Pages 247-257
ReviewAntibody-based therapies for infectious diseases : renaissance for an abandoned arsenal?Thérapies des maladies infectieuses basées sur les anticorps : renaissance pour un arsenal délaissé?
References (50)
- et al.
Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrom : results of a 12-month multicenter double-blind controlled trial
Blood
(1994) - et al.
Beneficial effects of intravenous immunoglobulins in AIDS
Lancet
(1992) - et al.
“Serum therapy” revisited : animal models of infection and the development of passive antibody therapy
Antimicrob. Agents Chemother.
(1994) - et al.
Return to the past: the case for antibody-based therapies in infectious diseases
Clin. Infect. Dis.
(1995) - et al.
Summary of antibody workshop: the role of humoral immunity in the treatment and prevention of emeerging and extant infectious diseases
J. Infect. Dis.
(1997) - et al.
Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
Transplantation
(1996) Human immunoglobulins for intravenous use and hepatitis C viral transmission
Clin. Diagn. Lab. Immunol.
(1994)- et al.
T cells cooperate with passive antibody to modify s infection in mice infection in mice
- et al.
Restoration of suppressor T-cell functions in children with AIDS following intravenous gamma globulin treatment
Am. J. Dis. Child.
(1986) - et al.
Effect of intravenous immunogloblulin (IVIG) on CD4+ lymphocyte decline in HIVinfected children in a clinical trial of IVIG infection prophylaxis
J. AIDS
(1993)
Intravenous immune globulin in symptomatic paediatric human immunodeficiency virus infection
Eur. J. Pediatr.
(1988)
Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies
Lancet
(1985)
Passsive immunotherapy in the treatment of advanced human immunodeficiency virus infection
J. Infect. Dis.
(1993)
Passive immunotherapy in AIDS: a double blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies versus transfusions of seronegative plasma
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns
J. Infect. Dis.
(1997)
Prevention of HIV infection by passive immununization with HIV immunoglobulin
AIDS Res. Hum. Retroviruses
(1991)
Primary isolates of human immunodeficieny virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
J. Virol.
(1995)
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
Nature (Lond.)
(1992)
Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies
J. AIDS
(1994)
A Phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120
J. Infect. Dis.
(1994)
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D
J. Virol.
(1994)
Crytic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization
J. Virol.
(1994)
The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4
J. Virol.
(1995)
A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection
N. Engl. J. Med.
(1994)
Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection
N. Engl. J. Med.
(1991)
Cited by (4)
The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics
2022, Leukemia Research ReportsCitation Excerpt :A number of modifications were proposed to promote the stability of nascent proteins either in the cytoplasm or the periplasm. A number of strains were genetically modified in order to secrete the native form of the antibody fragments as membrane-bound or extracellular which facilitated their separation and then their purification[71–73]. For that purpose, a number of “optimal host cell” models were developed using prokaryotic cells (especially Escherichia coli), yeast cell strains (Saccharomyces cerevisiae, Pichia pastoris), or mammalian cell lines (Chinese Hamster Ovary cells (CHO), Human Embryonic Kidney cells (HEK), and Murine Myeloma Cells)[68,74,75].
Passive antibody therapies: Progress and continuing challenges
1999, Clinical ImmunologyAdjunctive immune therapy for fungal infections
2001, Clinical Infectious Diseases
Copyright © 1997 Published by Elsevier Masson SAS